follow us
disclaim warranti liabil
due number sourc inform servic acquisdata pti ltd servic obtain
inher hazard electron distribut may delay omiss inaccuraci inform
servic acquisdata pti ltd affili agent sale repres distributor licensor
warrant accuraci complet current merchant abil fit particular purpos
inform servic avail acquisdata pti ltd servic event acquisdata pti ltd
affili agent sale repres distributor licensor liabl license anyon els loss
injuri caus whole part conting beyond control procur compil interpret edit write
report deliv inform servic acquisdata pti ltd servic event acquisdata
pti ltd affili agent sale repres distributor licensor liabl license anyon els
decis made action taken license relianc upon inform servic consequenti
special similar damag even advis possibl damag license agre liabil
acquisdata pti ltd affili agent sale repres distributor licensor aris kind
legal claim whether contract tort otherwis way connect acquisdata pti ltd servic shall
exceed amount license paid use acquisdata pti ltd servic twelv month immedi
preced event give rise claim
gilead scienc announc fourth quarter full year result
 fourth quarter product sale billion
 full year product sale billion
 full year dilut ep per share
 full year non-gaap dilut ep per share
foster citi calif -- busi -- feb inc announc today
result oper fourth quarter full year total revenu fourth quarter
billion compar billion period net incom fourth quarter million
earn per dilut share compar net loss billion loss per dilut share
period earn per share fourth quarter includ unfavor impact per
dilut share impair non-cash tax charg relat intang asset acquir kite pharma
inc kite non-gaap net incom fourth quarter billion per dilut share
compar billion per dilut share period
full year total revenu billion compar billion net incom
billion per dilut share compar billion per dilut share non-gaap net
incom billion per dilut share compar billion per dilut share
royalti contract revenu
net incom loss attribut gilead
non-gaap financi inform exclud acquisition-rel up-front collabor stock-bas compens
expens fair valu adjust market equiti secur discret tax charg benefit
associ chang tax relat law guidelin reconcili non- financi
inform provid tabl page
total product sale fourth quarter billion compar billion period
product sale fourth quarter billion unit state million europ
million locat product sale fourth quarter billion unit state
billion europ million locat
total product sale billion compar billion product sale
billion unit state billion europ billion locat product sale
billion unit state billion europ billion locat
hiv product saleswer billion fourth quarter compar billion period
hiv product sale billion compar billion increas primarili due
launch biktarvi bictegravir mg/emtricitabin mg/tenofovir alafenamid mg
continu uptak descovi emtricitabin mg/tenofovir alafenamid mg genvoya elvitegravir
mg/cobicistat mg/emtricitabin mg/tenofovir alafenamid mg odefsey emtricitabin
chronic hepat viru hcv product sale consist epclusa sofosbuvir mg/velpatasvir mg
sovaldi sofosbuvir mg million fourth quarter compar billion
period hcv product sale billion compar billion declin
primarili due lower averag net sell price lower sale volum harvoni epclusa across major
market result increas competit lower patient start
yescarta axicabtagen ciloleucel launch unit state octob gener million
sale fourth quarter million sale
product sale includ product gilead chronic hepat viru hbv cardiovascular oncolog
categori inclus vemlidi tenofovir alafenamid mg viread tenofovir disoproxil fumar
mg letairi ambrisentan mg mg ranexa ranolazin mg mg zydelig idelalisib
mg ambisom amphotericin liposom inject mg/vial million fourth quarter
compar million period product sale billion compar
billion
good sold product gross margin
good sold
non-gaap cost good sold
fourth quarter full year compar period
good sold non-gaap cost good sold increas primarili due reserv excess raw materi
inventori fourth quarter inventori reserv million approxim per dilut share
record excess raw materi primarili due sustain decreas demand harvoni full year
cost good sold also increas due amort expens relat intang asset acquir connect
gilead acquisit kite
product gross margin non-gaap product gross margin decreas primarili due factor note
research develop expens
sell gener administr sg expens
fourth quarter compar period
 expens increas primarili due million impair charg relat in-process ipr
program anti-bcma evalu treatment multipl myeloma up-front collabor
expens higher invest support growth gilead busi follow acquisit kite partial
off-set gilead purchas cell design lab inc
sg expens decreas primarili due lower stock-bas compens expens associ
acquisit kite partial off-set higher invest support growth gilead busi follow
acquisit kite
non-gaap expens non-gaap sg expens increas primarili due higher invest support
growth gilead busi follow acquisit kite
full year compar
 expens increas primarili due million impair charg relat ipr
program up-front collabor expens full year invest support growth gilead busi
follow acquisit kite higher stock-bas compens expens associ acquisit
sg expens increas primarili due full year invest support growth gilead busi
follow acquisit kite partial off-set lower acquisition-rel cost associ acquisit
non-gaap expens non-gaap sg expens increas primarili due full year invest
support growth gilead busi follow acquisit kite
equival market debt secur
decemb gilead billion cash cash equival market debt secur
compar billion decemb gilead gener billion oper cash
flow repaid billion debt paid cash dividend billion util billion stock repurchas
gilead provid full year guidanc guidanc product sale reflect anticip entri
gener version letairi ranexa unit state full year impact gener product contain
tenofovir disoproxil fumar certain european countri
million except percentag per share amount
dilut ep impact acquisition-rel up-front collabor stock-bas compens
expens
announc board director name daniel oday chairman board chief execut offic
effect march announc board director appoint gregg alton interim chief execut
offic period januari march
announc immuno-oncolog partnership agenu inc focus develop commerci
announc strateg collabor corpor discov develop highli specif
inhibitor transform growth factor beta activ treatment fibrot diseas
announc global strateg collabor inc discov develop commerci
pipelin innov target immuno-oncolog treatment patient cancer
product pipelin updat announc gilead fourth quarter includ
hiv liver diseas program
announc china nation medic product administr nmpa approv harvoni china
treatment hcv genotyp infect adult adolesc age year
announc nmpa approv descovi china treatment infect adult adolesc
announc nmpa approv vemlidi china treatment chronic hbv infect adult
present data liver meet includ announc
result studi investig epclusa hcv infect patient sever renal impair undergo dialysi
harvoni pediatr hcv patient age three five year ad efficaci safeti profil sofosbuvir-
result gilead hbv cure develop program
result gilead clinic develop program advanc fibrosi due nonalcohol steatohepat data
present support on-going develop gilead investig compound evalu util non-invasive
test identif patient advanc fibrosi demonstr signific burden diseas
result demonstr treatment investig select nonsteroid farnesoid receptor
agonist led signific improv liver biochemistri marker cholestasi patient primari
present data hiv glasgow confer includ announc result
phase random double-blind studi evalu safeti efficaci biktarvi treatment
infect treatment-nav adult on-going studi biktarvi found statist non-inferior
regimen dolutegravir emtricitabine/tenofovir alafenamid week therapi
oncolog cell therapi program
present data annual meet american societi hematolog includ announc
updat result single-arm phase studi evalu formerli
investig chimer antigen receptor cell therapi adult patient relaps refractori acut
lymphoblast leukemia median follow-up month follow singl infus
evalu patient achiev complet tumor remiss defin complet remiss cr cr incomplet
hematolog recoveri rate undetect minim residu diseas patient achiev complet tumor
remiss
two-year efficaci safeti data pivot trial yescarta patient refractori larg b-cell
lymphoma minimum follow-up two year singl infus yescarta median follow
month patient on-going respons
acquisdata proud host leagu estim want opportun win free
subscript join acquisdata media telecommun leagu
gilead research-bas biopharmaceut compani discov develop commerci innov medicin
area unmet medic need gilead product pipelin investig drug includ treatment
hiv/aid liver diseas seriou respiratori cardiovascular condit cancer inflamm market
product includ number categori first includ first complet treatment regimen hiv infect
avail once-daili singl pill first oral antiretrovir pill avail reduc risk acquir hiv
infect certain high-risk adult
acquisdata date busi intellig report cover develop world
report vast archiv corpor document list compani around world
global biopharmaceut compani develop deliv therapi patient
sever life-threaten diseas also ultra-rar alexion first commerci product soliri
eculizumab world first approv termin complement inhibitor today soliri approv nearli
countri treatment patient paroxysm nocturn hemoglobinuria pnh us european
union japan countri treatment patient atyp hemolyt urem syndrom ahu
discov develop manufactur deliv innov human therapeut use tool like advanc
human genet compani focus area high unmet medic need leverag biolog
manufactur expertis strive solut improv health outcom grown world
largest independ biotechnolog compani reach million patient around world develop
pipelin medicin breakaway potenti
biogen idec discov develop deliv patient world-wide innov therapi treatment
neurodegen diseas hemophilia autoimmun disord found world oldest
independ biotechnolog compani fortun compani billion annual revenu
biomarin found develop commerci innov biopharmaceut seriou diseas
medic condit compani four approv product naglazym galsulfas product wholli
develop commerci biomarin aldurazym laronidas develop joint ventur
genzym corpor kuvan sapropterin dihydrochlorid tablet develop partnership merck serono
divis merck kgaa darmstadt germani firdaps amifampridin approv
european commiss treatment lambert eaton myasthen syndrom
celgen global biopharmaceut compani discov develop commerci product treatment
cancer sever immun inflammatori condit clinic trial major medic
center use compound celgen
regeneron lead scienc technolog compani deliv life-transform medicin seriou diseas
found physician-scientist nearli year ago compani science-driven approach result four
fda-approv medicin numer product candid rang diseas includ ophthalmolog
rheumatoid arthriti atop dermat asthma pain cancer infecti diseas
seattl genet biotechnolog compani focus develop commerci innov empow
antibody-bas therapi treatment cancer industri leader antibody-drug conjug adc
technolog design har target abil monoclon antibodi deliv cell-kil agent directli
cancer cell adc intend spare non-target cell thu reduc mani toxic effect tradit
chemotherapi potenti enhanc antitumor activ addit one market product advanc
deep product pipelin address signific unmet medic need
seattl genet found headquart bothel washington suburb seattl
compani complet initi public offer march trade nasdaq stock market
symbol compani employe passion help peopl live cancer
shire lead global biotechnolog compani focus serv peopl rare diseas highli
special condit strive develop best-in-class product mani avail
storag disord gastrointestin intern medicin endocrin hereditari angioedema grow
franchis oncolog
vertex global biotechnolog compani discov develop commerci innov new medicin
treat seriou diseas found cambridg vertex today research develop site
commerci offic us canada europ australia four year row scienc magazin name
vertex one top employ life scienc
unit state largest market biopharmaceut account around third global market
world leader biopharmaceut accord pharmaceut research manufactur
associ phrma firm conduct half world pharmaceut billion hold
intellectu properti right new medicin overal econom impact biopharmaceut industri
 economi substanti industri account trillion econom output repres
percent total output total econom impact includ billion revenu
biopharmaceut busi billion supplier worker spend
peopl work biopharmaceut industri unit state across broad rang
occup includ scientif research technic support manufactur directli indirectli industri
support million job across unit state industri requir highly-skil educ
workforc administr level includ ph scientist third job sector key
unit state one world support domest environ develop
commerci pharmaceut minim market barrier strength includ intellectu properti
system reward innov patent data protect science-bas regulatori system
consid rigor world largest scientif research base foster academ institut
decad govern research fund robust capit market unit state attract major
global ventur capit invest start-up biopharmaceut enterpris
acquisdata date busi intellig report cover develop world
report vast archiv corpor document list compani around world
